Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Lymphoma

Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma

Bone Marrow Transplantation volume 50, pages 1299–1305 (2015)Cite this article

Subjects

Abstract

Allogeneic stem cell transplantation (allo-SCT) is a curative option for patients with relapsed follicular lymphoma (FL). Prospective studies of reduced-intensity conditioning (RIC) have revealed that chemosensitivity at allo-SCT is the most reliable predictor of outcome; however, limited data are available for progressive/refractory disease. We report here a retrospective analysis of RIC allo-SCT for patients with FL. The purpose of this study was to elucidate the role of allo-SCT for patients with relapsed/refractory FL. We analyzed 46 patients—11 (24%) transplanted in CR, 6 (13%) transplanted in PR and 29 (63%) with progressive/refractory disease. The estimated 5-year overall survival rate was 71.6% (95% confidence interval (CI), 51.5–84.5%). According to the disease status at transplantation, the 5-year survival rate was 80.7% (95% CI, 37.7–95.4%) in the patients with CR or PR and 66.1% (95% CI, 41.5–82.3%) in those with progressive/refractory disease (P=0.29). There were no differences in relapse/progression and non-relapse mortality between the patients with chemosensitive disease and progressive/refractory disease. Allo-SCT may be a valuable treatment option, even for patients with progressive/refractory FL.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. The world health organization classification of malignant lymphomas in japan: incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists. Pathol Int 2000; 50: 696–702.

  2. The Non-Hodgkin’s Lymphoma Classification Project. A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin’s Lymphoma. Blood 1997; 89: 3909–3918.

    Google Scholar 

  3. Armitage JO, Weisenburger DD . New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780–2795.

    Article  CAS  Google Scholar 

  4. Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007; 25: 1986–1992.

    Article  CAS  Google Scholar 

  5. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725–3732.

    Article  CAS  Google Scholar 

  6. Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26: 4579–4586.

    Article  CAS  Google Scholar 

  7. Schouten HC, Bierman PJ, Vaughan WP, Kessinger A, Vose JM, Weisenburger DD et al. Autologous bone marrow transplantation in follicular non-Hodgkin’s lymphoma before and after histologic transformation. Blood 1989; 74: 2579–2584.

    CAS  Google Scholar 

  8. Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008; 111: 4004–4013.

    Article  CAS  Google Scholar 

  9. Bastion Y, Brice P, Haioun C, Sonet A, Salles G, Marolleau JP et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 1995; 86: 3257–3262.

    CAS  Google Scholar 

  10. Rohatiner AZ, Nadler L, Davies AJ, Apostolidis J, Neuberg D, Matthews J et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol 2007; 25: 2554–2559.

    Article  Google Scholar 

  11. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008; 111: 5530–5536.

    Article  CAS  Google Scholar 

  12. Shea T, Johnson J, Westervelt P, Farag S, McCarty J, Bashey A et al. Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901. Biol Blood Marrow Transplant 2011; 17: 1395–1403.

    Article  Google Scholar 

  13. Thomson KJ, Morris EC, Milligan D, Parker AN, Hunter AE, Cook G et al. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellen long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol 2010; 28: 3695–3700.

    Article  Google Scholar 

  14. Piñana JL, Martino R, Gayoso J, Sureda A, de la Serna J, Díez-Martín JL et al. Reduced-intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. Haematologica 2010; 95: 1176–1182.

    Article  Google Scholar 

  15. Ono Y, Mori T, Kato J, Yamane A, Shimizu T, Kikuchi T et al. Long-term follow-up of reduced-intensity allogeneic hematopoietic stem cell transplantation for refractory or relapsed follicular lymphoma. Am J Hematol 2012; 87: 929–931.

    Article  Google Scholar 

  16. Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15: 367–369.

    Article  Google Scholar 

  17. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244–1253.

    Article  CAS  Google Scholar 

  18. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579–586.

    Article  Google Scholar 

  19. Kanda Y . Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 2013; 48: 452–458.

    Article  CAS  Google Scholar 

  20. Sebban C, Mounier N, Brousse N, Belanger C, Brice P, Haioun C et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2006; 108: 2540–2544.

    Article  CAS  Google Scholar 

  21. Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnsen HE et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3918–3927.

    Article  CAS  Google Scholar 

  22. Le Gouill S, De Guibert S, Planche L, Brice P, Dupuis J, Cartron G et al. Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. Haematologica 2011; 96: 1128–1135.

    Article  Google Scholar 

  23. Fowler N, Kahl BS, Lee P, Matous JV, Cashen AF, Jacobs SA et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol 2011; 29: 3389–3395.

    Article  CAS  Google Scholar 

  24. Forstpointner R, Unterhalt M, Dreyling M, Böck HP, Repp R, Wandt H et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108: 4003–4008.

    Article  CAS  Google Scholar 

  25. Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99: 4336–4342.

    Article  CAS  Google Scholar 

  26. Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin’s lymphomas. J Clin Oncol 2005; 23: 7565–7573.

    Article  CAS  Google Scholar 

  27. Vose JM, Bierman PJ, Loberiza FR, Lynch JC, Bociek GR, Weisenburger DD et al. Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index. Biol Blood Marrow Transplant 2008; 14: 36–42.

    Article  Google Scholar 

  28. Robinson SP, Canals C, Luang JJ, Tilly H, Crawley C, Cahn JY et al. The outcome of reduced-intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. Bone Marrow Transplant 2013; 48: 1409–1414.

    Article  CAS  Google Scholar 

  29. van Besien K, Loberiza FR Jr, Bajorunaite R, Armitage JO, Bashey A, Burns LJ et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003; 102: 3521–3529.

    Article  CAS  Google Scholar 

  30. Tomblyn MR, Ewell M, Bredeson C, Kahl BS, Goodman SA, Horowitz MM et al. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete remission or first partial remission. Biol Blood Marrow Transplant 2011; 17: 1051–1057.

    Article  Google Scholar 

  31. Noriega V, Kaur H, Devereux S, Byrne J, Marcus R, Haynes A et al. Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma. Leuk Res 2014; 38: 737–743.

    Article  Google Scholar 

  32. Ingram W, Devereux S, Das-Gupta EP, Russell NH, Haynes AP, Byrne JL et al. Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. Br J Haematol 2008; 141: 235–243.

    Article  Google Scholar 

  33. Evens AM, Vanderplas A, LaCasce AS, Crosby AL, Nademanee AP, Kaminski MS et al. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. Cancer 2013; 119: 3662–3671.

    Article  CAS  Google Scholar 

  34. Cordonnier C, Chevret S, Legrand M, Rafi H, Dhédin N, Lehmann B et al. Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Ann Intern Med 2003; 139: 8–18.

    Article  CAS  Google Scholar 

  35. Riihijärvi S, Taskinen M, Jerkeman M, Leppä S . Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy. Eur J Haematol 2011; 86: 124–128.

    Article  Google Scholar 

Download references

Acknowledgements

We thank the medical, nursing, data processing and laboratory staff at the Kanto Study Group for Cell Therapy in Japan.

Author information

Authors and Affiliations

  1. Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan

    S Yano & T Saito

  2. Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan

    T Mori, J Kato & S Okamoto

  3. Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan

    Y Kanda

  4. Division of Hematology, Department of Clinical Cell Biology, Chiba University Graduate School of Medicine, Chiba, Japan

    C Nakaseko

  5. Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan

    S Fujisawa

  6. Department of Hematology, Yokohama City University Graduate School of Medicine, Yokohama, Japan

    N Tomita

  7. Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan

    R Sakai

  8. Department of Hematology, Chiba Aoba Municipal Hospital, Chiba, Japan

    K Shono

  9. Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Maebashi, Japan

    T Saitoh

  10. Department of Hematology, Narita Red Cross Hospital, Chiba, Japan

    N Aotsuka

  11. Leukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan

    N Kobayashi

  12. Division of Molecular Therapy, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

    S Takahashi

  13. Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan

    H Kanamori

Authors
  1. S Yano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y Kanda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Nakaseko
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Fujisawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N Tomita
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R Sakai
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. K Shono
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. T Saitoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. N Aotsuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. N Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. T Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. S Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. H Kanamori
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. S Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Kanto Study Group for Cell Therapy (KSGCT)

Corresponding author

Correspondence to S Yano.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yano, S., Mori, T., Kanda, Y. et al. Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma. Bone Marrow Transplant 50, 1299–1305 (2015). https://doi.org/10.1038/bmt.2015.158

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2015.158

Search

Advanced search

Quick links